Needham & Company
-
Pernix Therapeutics (PTX) Bullish Stance Reiterated at Needham & Company Following Zohydro ER Deal
-
Pernix Therapeutics (PTX) Target Price Lifted to $16 at Needham & Company
-
Pernix Therapeutics (PTX) Bullish Stance Reiterated at Needham & Company on Deal Closing
-
Notable 52-Week Highs and Lows of the Day 05/15: (PTX) (WIN) (ORCL) High; (LIQD) (MCP) (SFXE) Low
-
Notable Analyst Rating Changes 05/15: (PLUG) (PTX) (TWTR) Upgraded; (BMY) (HII) (CXP) Downgraded
-
Needham & Company Upgrades Pernix Therapeutics (PTX) to Strong Buy
-
Pernix Therapeutics (PTX) Shifiting To Offense, Needham & Company Says
-
Unusual 11 Mid-Day Movers 03/18: (GERN) (XGTI) (BGMD) Higher; (GGS) (KIOR) ETAK) Lower
-
Pernix Therapeutics (PTX) Target Price Bumped Higher at Needham & Company
-
Pernix Therapeutics (PTX) Bullish Stance Reiterated at Needham & Company
-
Pernix Therapeutics (PTX) PT Lowered at Needham & Company; 'Buy' Maintained
-
Needham & Company Maintains a 'Buy' on Pernix Therapeutics (PTX); Don't Call It A Comeback
-
Needham & Company Maintains a 'Buy' on Pernix Therapeutics (PTX); Price Increase On Cedax Franchise Provides Solid Near-Term Buffer
-
Needham & Company Maintains a 'Buy' on Pernix Therapeutics (PTX); Acquisition Adds Strategic Muscle On Manufacturing & Development Side
-
Needham & Company Maintains a 'Buy' on Pernix Therapeutics (PTX); Upside Scenarios Outweigh Downside Risks
-
Needham & Company Maintains a 'Buy' on Pernix Therapeutics (PTX); Adjusting Estimates After Q4 Results
-
Needham & Company Maintains a 'Buy' on Pernix Therapeutics (PTX); Continues Winning Top Line Ways
-
Needham & Company: Specialty Pharmaceuticals - 2012 Preview: European Hangover Expected to Ease; Valuations Reflect Fear Not Fact
-
Needham & Company Starts Pernix Therapeutics (PTX) at Buy; Kid is Hot Tonight; Hitting Stride as Recent Launches Provide Leverage